{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:59:30Z","timestamp":1791413970923,"version":"4.3.3"},"reference-count":64,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Therapeutic monoclonal antibodies (MAbs) are an important class of drugs used to treat diseases ranging from autoimmune disorders to B cell lymphomas to other rare conditions thought to be untreatable in the past. Many advances have been made in the characterization of immunoglobulins as a result of pharmaceutical companies investing in technologies that allow them to better understand MAbs during the development phase. Mass spectrometry is one of the new advancements utilized extensively by pharma to analyze MAbs and is now beginning to be applied in the clinical laboratory setting. The rise in the use of therapeutic MAbs has opened up new challenges for the development of assays for monitoring this class of drugs. MAbs are larger and more complex than typical small-molecule therapeutic drugs routinely analyzed by mass spectrometry. In addition, they must be quantified in samples that contain endogenous immunoglobulins with nearly identical structures. In contrast to an enzyme-linked immunosorbent assay (ELISA) for quantifying MAbs, mass spectrometry-based assays do not rely on MAb-specific reagents such as recombinant antigens and\/or anti-idiotypic antibodies, and time for development is usually shorter. Furthermore, using molecular mass as a measurement tool provides increased specificity since it is a first-order principle unique to each MAb. This enables rapid quantification of MAbs and multiplexing. This review describes how mass spectrometry can become an important tool for clinical chemists and especially immunologists, who are starting to develop assays for MAbs in the clinical laboratory and are considering mass spectrometry as a versatile platform for the task.<\/jats:p>","DOI":"10.1128\/cvi.00545-16","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T01:45:54Z","timestamp":1489023954000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":71,"title":["Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory"],"prefix":"10.1128","volume":"24","author":[{"given":"Paula M.","family":"Ladwig","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Barnidge","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A. V.","family":"Willrich","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/9783527675272.ch08","volume-title":"Therapeutic Fc-Fusion Proteins","author":"Berry JD","year":"2014","unstructured":"Berry JD . 2014. Introduction to therapeutic Fc-fusion proteins, p 217\u2013232. InChamowSMRyllTLowmanHBFarsonD (ed), Therapeutic Fc-Fusion Proteins. Wiley-VCH Verlag GmbH & Co. KGaA,Weinheim, Germany."},{"key":"e_1_3_2_3_2","first-page":"1","volume-title":"Therapeutic Fc-fusion proteins","author":"Rajpal A","year":"2014","unstructured":"Rajpal A StropPYeungYAChaparro-RiggersJPonsJ. 2014. Introduction: antibody structure and function, p 1\u201344. InChamowSMRyllTLowmanHBFarsonD (ed), Therapeutic Fc-fusion proteins. Wiley-VCH Verlag GmbH & Co. KGaA,Weinheim, Germany."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1114320"},{"key":"e_1_3_2_5_2","first-page":"75","volume-title":"Cellular and molecular immunology","author":"Abbas AK","year":"2007","unstructured":"Abbas AK LichtmanAHPillaiS. 2007. Cellular and molecular immunology,6th ed, p 75\u201396. Saunders Elsevier,Philadelphia, PA.","edition":"6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-016-7388-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.328"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.152116"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1023"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr5005967"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.253740"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1031"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000855"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.06.032"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.09.006"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.114"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304094"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0829-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.211"},{"key":"e_1_3_2_23_2","first-page":"1","article-title":"Monitoring therapeutic MAbs: IBD treatments provide example for clinical laboratory's new role","volume":"2016","author":"Willrich M","year":"2016","unstructured":"Willrich M SnyderM. 2016. Monitoring therapeutic MAbs: IBD treatments provide example for clinical laboratory's new role. Clin Forensic Toxicol News2016:1\u20136.","journal-title":"Clin Forensic Toxicol News"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31828d23c3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12030"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.06.002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.242875"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.12.015"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13361-016-1531-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac00101a008"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9673(94)01287-O"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac00077a003"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0231(19991230)13:24<2503::AID-RCM818>3.0.CO;2-W"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)01168-7"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac026154+"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr049963d"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0832254100"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac702115b"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac800205s"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1700"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M112.019620"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac201293m"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac070483q"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9948-4"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac503158g"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.05.017"},{"key":"e_1_3_2_47_2","first-page":"19","article-title":"Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry","volume":"30","author":"Pitt JJ","year":"2009","unstructured":"Pitt JJ . 2009. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev30:19\u201334.","journal-title":"Clin Biochem Rev"},{"key":"e_1_3_2_48_2","first-page":"3","article-title":"Electrospray ionisation mass spectrometry: principles and clinical applications","volume":"24","author":"Ho CS","year":"2003","unstructured":"Ho CS LamCWChanMHCheungRCLawLKLitLCNgKFSuenMWTaiHL. 2003. Electrospray ionisation mass spectrometry: principles and clinical applications. Clin Biochem Rev24:3\u201312.","journal-title":"Clin Biochem Rev"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-007-1248-5"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2787(200007)19:4<165::AID-MAS1>3.0.CO;2-Y"},{"key":"e_1_3_2_51_2","volume-title":"A framework for using CLSI documents to evaluate clinical laboratory measurement procedures","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. A framework for using CLSI documents to evaluate clinical laboratory measurement procedures,2nd ed. CLSI report EP 19. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"2"},{"key":"e_1_3_2_52_2","volume-title":"User verification of performance for precision and trueness; approved guideline\u20142nd ed","author":"CLSI","year":"2006","unstructured":"CLSI. 2006. User verification of performance for precision and trueness; approved guideline\u20142nd ed. CLSI document EP15-A2. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_53_2","volume-title":"Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline","author":"CLSI","year":"2007","unstructured":"CLSI. 2007. Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline. CLSI document C50-A. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_54_2","volume-title":"Measurement procedure comparison and bias estimation using patient samples; approved guideline\u20143rd ed","author":"CLSI","year":"2013","unstructured":"CLSI. 2013. Measurement procedure comparison and bias estimation using patient samples; approved guideline\u20143rd ed. CLSI document EP09-A3. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_55_2","volume-title":"Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline","author":"CLSI","year":"2003","unstructured":"CLSI. 2003. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI document EP06-A. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_56_2","volume-title":"Defining, establishing and verifying reference intervals in the clinical laboratory; approved guideline\u20143rd ed","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Defining, establishing and verifying reference intervals in the clinical laboratory; approved guideline\u20143rd ed. CLSI document C28-A3c. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_57_2","volume-title":"Liquid-chromatography-mass spectrometry methods; approved guideline","author":"CLSI","year":"2014","unstructured":"CLSI. 2014. Liquid-chromatography-mass spectrometry methods; approved guideline. CLSI document C62-A. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M500331-MCP200"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.222208"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.07.007"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr5000544"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b00544"},{"key":"e_1_3_2_63_2","first-page":"565","volume-title":"Neoplastic diseases of the blood","author":"Katzmann JA","year":"2012","unstructured":"Katzmann JA KyleRALustJASnyderMDispenzieriA. 2012. Immunoglobulins and laboratory recognition of monoclonal proteins, p 565\u2013588. InWiernikPHGoldmanJMDutcherJPKyleR (ed), Neoplastic diseases of the blood,5th ed. Springer Science & Business Media,New York, NY.","edition":"5"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13361-016-1566-y"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.01.031"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00545-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00545-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:07:53Z","timestamp":1692716873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00545-16"}},"subtitle":[],"editor":[{"given":"Christopher J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/CVI.00545-16"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00545-16","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2017-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}